Impact of Recombinant VSV-HIV Prime, DNA-Boost Vaccine Candidates on Immunogenicity and Viremia on SHIV-Infected Rhesus Macaques
Authors:
- Alice BergerABAlice Berger
- Jannie PedersenJPJannie Pedersen
- Monika M. KowatschMKMonika M. Kowatsch
- Florine ScholteFSFlorine Scholte
- Marc-Alexandre LafranceMLMarc-Alexandre Lafrance
- Hiva AziziHAHiva Azizi
- Yue LiYLYue Li
- Alejandro GomezAGAlejandro Gomez
- Matthew WadeMWMatthew Wade
- Hugues Fausther-BovendoHFHugues Fausther-Bovendo
- Marc-Antoine de La VegaMVMarc-Antoine de La Vega
- Joseph JelinskiJJJoseph Jelinski
Open Access
Abstract
Currently, no effective vaccine to prevent human immunodeficiency virus (HIV) infection is available, and various platforms are being examined. The vesicular stomatitis virus (VSV) vaccine vehicle can induce robust humoral and cell-mediated immune responses, making it a suitable candidate for the development of an HIV vaccine. Here, we analyze the protective immunological impacts of recombinant VSV vaccine vectors that express chimeric HIV Envelope proteins (Env) in rhesus macaques. To improve the immunogenicity of these VSV-HIV Env vaccine candidates, we generated chimeric Envs containing the transmembrane and cytoplasmic tail of the simian immunodeficiency virus (SIV), which increases surface Env on the particle. Additionally, the Ebola virus glycoprotein was added to the VSV-HIV vaccine particles to divert tropism from CD4 T cells and enhance their replications both in vitro and in vivo. Animals were boosted with DNA constructs that encoded matching antigens. Vaccinated animals developed non-neutralizing antibody responses against both the HIV Env and the Ebola virus glycoprotein (EBOV GP) as well as systemic memory T-cell activation. However, these responses were not associated with observable protection against simian-HIV (SHIV) infection following repeated high-dose intra-rectal SHIV SF162p3 challenges.Keywords
Funding Information
- Canadian Institutes of Health Research (OVV-152411, 7025-00079B)
- Danmarks Frie Forskningsfond (OVV-152411, 7025-00079B)
This publication has 54 references indexed in Scilit:
- A novel DNA platform designed for vaccine use with high transgene expression and immunogenicityVaccine, 2021
- Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell culturesVaccine, 2020
- Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV ChallengeCell Reports, 2020
- rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessmentVaccine: X, 2019
- Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody TitersImmunity, 2019
- HIV/AIDS Vaccines: 2018Clinical Pharmacology & Therapeutics, 2018
- CD69: from activation marker to metabolic gatekeeperEuropean Journal of Immunology, 2017
- Human Adaptation of Ebola Virus during the West African OutbreakCell, 2016
- Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virusVirology, 2015
- CD40-CD40 ligandJournal of Leukocyte Biology, 2000